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a b s t r a c t
Moxiﬂoxacin (MFX) is a potential oral agent use in the treatment of multidrug-resistance tuberculosis
(MDR-TB). Due to variability in pharmacokinetics and in vitro susceptibility of causative bacteria, thera-
peutic drugmonitoring (TDM) of MFX is recommended. Conventional plasma sampling for TDM is facing
logistical challenges, especially in limited resource areas, and dried blood spots (DBS) samplingmay offer
a chance to overcome this problem. The objective of this study was to develop a LC–MS/MS method for
determination of MFX in dried blood spots (DBS) that is applicable for TDM. The inﬂuence of paper type,
the hematocrit (Hct) and the blood volume per spot (Vb) on the estimated blood volume in a disc (Vest)
was investigated. The extracts of 8mm diameter discs punched out from DBS were analyzed using liquid
chromatography tandemmass spectrometry (LC–MS/MS)with cyanoimipramin as internal standard. The
method was validated with respect to selectivity, linearity, accuracy, precision, sensitivity, recovery and
stability. The effect of Hct and Vb on LC–MS/MS analytical result was also investigated. The relationship
betweenMFX concentrations in venous and ﬁnger prick DBS and those in plasmawas clinically explored.
Vest was highly inﬂuenced by Hct while the effect of Vb appeared to be different among paper types.
Calibration curves were linear in the range of 0.05–6.00mg/L with inter-day and intra-day precisions
and biases of less than 11.1%. The recovery was 84.5, 85.1 and 92.6% in response to blood concentration
of 0.15, 2.50 and 5.00mg/L, respectively. A matrix effect of less than 11.9% was observed. MFX in DBS
was stable for at least 4weeks at room condition (temperature of 25 ◦C and humidity of 50%). A large
range of Hct value produced a signiﬁcant analytical bias and it can be correctedwith resulting DBS size. A
good correlation betweenDBS and plasma concentrationswas observed and comparable results between
venous DBS and ﬁnger prick DBS was attained. This fully validated method is suitable for determination
of MFX in dried blood spot and applicable for TDM.. Introduction
Fluoroquinolones play a crucial role in MDR-TB treatment reg-
ment [1]. Moxiﬂoxacine (MFX) is one of the most promising
rug of this group with high in vitro and in vivo activity and is
ell tolerated [2–4]. Furthermore, MFX may be useful in exten-
ively drug-resistant tuberculosis (XDR-TB) [5]. MFX appeared to
e effective in shortening tuberculosis treatment if it is added to
r substituted for an agent in the standard regimen [6]. In selected
atient populations (e.g. HIV and tuberculosis meningitis), MFX is
potential candidate to become part of the routine treatment [7,8].
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Although MFX is frequently used in the treatment of tubercu-
losis, the optimal dosage of MFX in tuberculosis treatment is not
clearly deﬁned [9]. The in vitro pharmacodynamic infection model
showed optimized efﬁcacy using a dosage of 800mg per day, while
400mg per day is given in daily practice [1,7,9]. Furthermore, a sig-
niﬁcantdrop inareaunder thecurve (AUC)ofMFXof approximately
30% is observed if rifampicin as an enzyme inducer is administered
concomitantly [10]. Taking these facts in consideration, a TDMmay
help toavoid too lowblood levels and to improve the treatmentout-
comes [11]. Unfortunately, facilities for determination drug level in
remote rural areas are not available. As blood samples are normally
unstable at room temperature and cooled shipment is not feasible,
the application of DBS sampling is a potential solution to overcome
these logistical problems. Although MFX is stable in plasma at the
room temperature for at least 5days [12] long distance transport
may takemore time or room temperaturemay be exceeded during
transport. DBS sampling has also other advantages including easily























































Time (min) Buffer (%) Water (%) Acetonitrile (%)
0 5 95 0
0.5 5 35 60
1.6 5 35 60
1.61 5 0 95064 D.H. Vu et al. / J. Chroma
o perform; lower risk of infection and the required blood sam-
le volume is smaller [13,14]. Although the inﬂuence of Hct and
olume of the bloodspot (Vb) were emphasized as potential con-
ounding factors, these may vary for each drug. Therefore Hct and
b need to be investigated in DBS method development [13–19].
Up tonow,DBSmethodhadbeendeveloped for thepharmacoki-
etics and TDM of a number of drugs [13,14,20]. As DBS proved
ts value in TDM of HIV drugs it may also help to optimize the
reatment of tuberculosis (TB), especially with MDR-TB.
Clinical validation is highly recommended for DBS method
evelopment because Hct, viscosity, and components of blood
ay vary between patients. In the clinical validation the relation
etween the plasma concentration and the concentration of the
rug inwholeblood (plasma–blood cell partition coefﬁcient) canbe
etermined. The result obtained with DBS can be translated to the
eference value which have been determined in serum or plasma
alue using the blood/plasma ratio [14].
The objectives of our study are to develop a LC–MS/MS method
or determination of MFX in DBS, and to investigate the effect of
nﬂuencing factors on DBS method development.
. Materials and methods
.1. Chemicals and reagents
Moxiﬂoxacin hydrochloride was provided by Bayer AG (Berlin,
ermany). The internal standard, cyanoimipramine, was sup-
lied by Roche (Woerden, The Netherlands). Acetonitrile (ACN)
ichrosolve and water for LC/MS were purchased from Bio-
olve (Valkenswaard, The Netherlands). The chemicals, including
ethanol (MeOH) Lichrosolve and triﬂuoroacetic anhydride, were
f HPLC or analytical grade and were obtained from VWR (Amster-
am, The Netherlands). Three types of paper, including Whatman
1ETCHR,Whatman903andWhatmanN03wereused. Thepunch-
ng machine (punch diameter =8mm) was supplied by Technical
upport Facilities of the University of Leiden (NL) and designed
y P.M. Edelbroek PhD, (Heemstede, the Netherlands) [14]. Packed
ed blood cells and pooled human serum were provided by the
epartment of Haematology, UniversityMedical Center Groningen
ccording to local regulations.
.2. Sample preparation
Stock solutions of MFX were prepared as stock A and stock B by
issolving MFX HCl in water at concentration of 200mg/L in order
omake calibration standards andquality control (QC) samples. The
tock solutions were diluted to working stock solutions of 10mg/L
working stock A1 and B1).
Packed red blood cells (RBC) were centrifuged and the preserv-
ng solution was discarded. The subsequent cells were washed
hree times with physiological buffer and one time with serum
efore adding a precise volume of serum to produce blood with
he Hct of 20, 35 and 50%.
Calibration blood was prepared at concentrations of 0.05, 0.15,
.50, 1.00, 2.00, 3.50, 5.00 and 6.00mg/L by adding stock solution
or A1. QC samples, including LLOQ (lower limit of quantitation),
OW, MED, HIGH, OC (over the calibration curve) at concentration
f 0.05, 0.15, 2.50, 5.00 and 10.00mg/L, respectively,were prepared
rom stock solution B and B1 by the same method. All tests for
he validation were performed using the Hct of 35% except for the
valuation of the Hct effect itself.
To prepare a DBS, 50L of blood was transferred onto paper
y an Eppendorf pipette. It was left to dry for at least 3h at room
emperature and then preserved in a sealed plastic bags at −80 ◦C.
achQC levelwas prepared in six folds ofwhich ﬁvewere analyzed.2.9 5 0 95
2.91 5 95 0
3.5 5 95 0
Theextracting solution consistedof cyanoimipramine0.03mg/L
in a mixture of methanol and water (9:1, v/v). An 8mm diameter
disc was punched out from the DBS and was then transferred to
an 1.5mL Eppendorf tube where 300L of extracting solution was
added. Theextractionwasacceleratedby60minof sonication.After
sonication 200L of the extractwas transferred to a polypropylene
vial and 5L was injected into the LC–MS/MS system.
2.3. Equipment and conditions
All samples were analyzed on a Thermo Fisher Scientiﬁc TSQ
Quantum Discovery (Waltham, US) triple quadrupole LC–MS/MS
with a Thermo Surveyor MS pump and a surveyor plus autosam-
pler with a set temperature of +20 ◦C. Analyses were performed
on a 50mm×2.1mm HyPurity C18 5-m analytical column (Inter-
science Breda, the Netherlands). The mobile phase at ﬂow rate of
0.3mL/min consisted of puriﬁedwater, acetonitrile and an aqueous
buffer (containing ammonium acetate 10g/L, acetic acid 35mg/L
and triﬂuoracetic anhydride 2mL/L water). The buffer was main-
tained constant at 5% during the gradient (Table 1).
The Thermo TSQ Quantum Discovery mass selective detector
was used in positive ion mode and performed selected reac-
tion monitoring as scanning mode. The mass parameters of m/z
402.0–358.2 (collision energy 19eV) and m/z 306.0–218.0 (colli-
sion energy 39eV) were measured with scan width of 0.5m/z for
MFX and cyanoimipramine detection. Ion spray voltage, sheath gas
pressure, auxiliary gas pressure and capillary temperaturewere set
at 3500V, 35 arb (arbitrary units), 5 arb and 350 ◦C, respectively.
Peak height integration and quantiﬁcation of the componentswere
achieved with Xcalibur software version 1.4. SRI (Thermo Fisher
Scientiﬁc, Waltham, US).
2.4. Method development and validation
2.4.1. Method development
To determine MFX in a DBS, a ﬁxed diameter disc is punched
out from DBS. Normally, it is assumed that blood volumes in dif-
ferent discs are equal. However, paper type, blood viscosity, that
mostly relates to Hct, and Vb, were possible factors introducing
analytical bias [14,19,23]. As a consequence, we evaluated the vari-
ation in disc-weight and blood spreading with three types of paper
including Whatman grade 3, Whatman 31ET CHR and Whatman
903.
From each of six paper cards taken randomly, six blank paper
discs were punched out and scaled to determine disc-weight vari-
ation. In addition, a precise blood volume of 10, 15, 20, 25, 30, 35,
40, 45, 50, 55 and60Lwith aHct of 20, 35 and50%waspipettedon
the paper in 6 fold. From both sides of the blood spots, imageswere
taken using a Nikkon D60 camera. Areas of blood spots were mea-
®sured by image analysis using ImageJ software (version 1.42q).
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n Eq. (1), d is the diameter of the punch (8mm); Vb and SDBS are
lood volume and respective DBS area. For each type of paper, lin-
ar regression analysis was performed to estimate the effect of the
wo parameters, Hct and Vb, on the variation of Vest. The changes
f Vest over the investigated range of Hct and Vb were calculated
s ErrorHct = HctbHct/V¯est and ErrorVb = VbbVb /V¯est, respectively.
n which, V¯est is the average of Vest. Hct and Vb are the differ-
nces between the lowest and the highest values of Hct and Vb that
ere investigated, respectively; bHct and bVb are unstandardized
egression coefﬁcients of Hct and Vb.
To develop the extractionmethod, different extracting solutions
ncluding MeOH, ACN, water, the mixture of ACN:MeOH (16:84,
/v) and the mixtures of MeOH:water (10:90 and 20:80, v/v) were
ested with a sonication time of 30min. The extracting solution
as selected based on the visual signs and the chromatographic
esponse of the extraction. With this extracting solution, the son-
cation time of 0, 10, 30, 60 and 100min was evaluated and the
ptimal value was selected. The DBS at concentration of 2.5mg/L
as used in the method development.
.4.2. Method validation
The method was validated in terms of linearity, selectivity
nd speciﬁcity, accuracy, precision, dilution integrity, carry-over,
rocess efﬁciency and stability [21]. Validation was performed
ith a maximum tolerated bias and coefﬁcient of variation (CV)
f 20% for the LLOQ and 15% for the other validation concen-
rations. In addition, the inﬂuence of Hct and Vb were also
valuated.
Oneachof threeconsecutivedays, a single calibrationcurvewith
ight concentration levels was analyzed. Calibration curves were
hen established using 1/x weighted linear regression. Peak height
atios ofMFX and the internal standardwere used to calculate con-
entrations. Inter and intra-day reproducibility was evaluated at
LOQ, LOW, MED, HIGH and OC levels. The extract at OC level was
iluted ten times with the extract of a blank DBS and the analytical
esult was then multiplied by ten to correct for the dilution. Selec-
ivity and speciﬁcity were evaluated by analyzing blank and LLOQ
BS samples prepared from ﬁve different batches of real human
lood. The carry-over was estimated by injecting a blank sample
ve times after analyzing a HIGH-level sample.
To calculate the process efﬁciency, 10L of blank and QC (LOW,
EDandHIGH)bloodwereused tomakeaspot. Thewhole spotwas
unched out and extracted. Process efﬁciency, which was deﬁned
s matrix effect and recovery, was calculated from peak height
esponses of three solutions (A, B and C). Solution Awas the extract
f 10L-QC DBS in extracting solution. Solution B was the mixture
fMFX stock solution and the extracting solution at concentrations
qual to nominal values of solution A. Solution C was the extract
f 10L-blank DBS which was extracted by solution B. The matrix
ffect and recovery were determined as: matrix effect = (C−B)/B;
ecovery =A/C [13].
In addition, the matrix effect was also investigated by inject-
ng the extracts of ﬁve DBS samples derived from ﬁnger pricks of
FX freevolunteerswhileMFXandcyanoimipramineneat solution
ere post-column infused [22].
The stability of processed samples after 24 and 48h stored in the
uto-samplerwasevaluatedby re-injecting theextracts of previous
ays and calibrated by a freshly prepared calibration curve. Long-
erm stability was investigated for −80 ◦C, room condition (25 ◦C
nd 50% of humidity), high temperature (50 ◦C) and high humidity
∼100% at room temperature) at 2weeks and 4weeks after DBS
reparation. High humidity environment was created by storing
BS in a sealed plastic bag with wet tissues without contacting
ith DBS paper and monitored by a hygrometer.879 (2011) 1063–1070 1065
2.5. Inﬂuence of Hct and Vb
Tuberculosis patients have a relatively low Hct value of approx-
imately 35±6% [23]. For this reason, Hct values of 20, 25, 30, 35, 40,
45 and 50% were evaluated using the same experiment described
in Section 2.4.1. A linear regression equation between Vest and Hct
was constructed. Furthermore, the QC level of LOW,MED andHIGH
at each Hct value were prepared, analyzed and calibrated by cali-
bration samples with a Hct of 35%. The result was then corrected
by the following equation:
Ccorrected = Cobserved
Vstd
Vstd + b(Hct − 35)
(2)
Ccorrected is the concentration after correcting for Hct; Cobserved is
the concentration before correcting for Hct; Vstd is the Vest at stan-
dardized Hct (35%); Hct is the Hct of corrected sample; b is the
regression coefﬁcient between Vest (L) and Hct (%).
Blood volumes of 30, 50 and 100Lwere used tomake different
DBS sizes. Discs were punched out from the central part of the DBS
and analyzed in ﬁve fold. Calibration samples with a blood volume
of 50L were used to evaluate the inﬂuence of Vb.
2.6. Clinical validation
The samples for clinical validation were taken from tuberculo-
sis patients who received MFX 400mg once daily orally as part of
their treatment. The study protocolwas approved by the local insti-
tutional ethics committee.Written informed consentwas obtained
from the patients. Venous blood sampling with a volume of about
3mL was performed by nurses before the intake of the drug and at
1, 2, 3, 4 and 8h after oral administration. At each sampling time,
a venous DBS was prepared by pipetting 50L of the venous blood
onto the paper. The remaining venous blood was centrifuged at
3000 rpmand theplasmawaswithdrawnand stored at−20 ◦Cuntil
analysis. In addition, at the time of pre-dosing, 2 and 8h post-dose,
ﬁnger pricks were taken and blood was dropped directly on the
paper to make the ﬁnger prick DBS. The DBS were left dried for at
least 3h then stored in a sealed plastic bag at −80 ◦C before anal-
ysis. The DBS samples were analyzed using the developed method
and the plasma samples were analyzed by the routine analytical
method in our laboratory [12]. The correlations between venous
DBS, DBS from ﬁnger prick and plasma concentrations were eval-
uated by simple linear regression and Passing-Bablok regression
with the help of Analyse-it® software.
3. Results
3.1. Method development
The evaluation of the different types of ﬁlter paper showed that
discweight relates to the paper’s thickness and itsmatrix. The vari-
ation in disc weight may contribute to the variation of Vest and
subsequently to the analytical result. Among the three types of
paper tested theWhatman31ETCHRshowed the smallest variation
in disc weight with a CV of 2.3% (Table 2).
With the assumption that blood equally spreads from the center
toperipheral of theDBS,Vest apparently represents bloodvolume in
a punched disc. Linear regression analysis showed that Hct and Vb
highly contributed to the variation of Vest but was not equal among
different types of paper. Whatman 31ET CHR showed the highest
R2 of 0.89 whichmeans 89% of variation in Vest can be explained by
the regressionmodel for this type of paper. Furthermore, the effect
of the Vb was of no signiﬁcant inﬂuence (ˇVb = 0.03, p=0.246) sug-
gesting that blood equally spreads on this paper regardless the size
of DBS. In contrast, Hct is an important predictor which explains
88% (equal to ˇ2Hct) of total variation of the Vest. If the results are
1066 D.H. Vu et al. / J. Chromatogr. B 879 (2011) 1063–1070
Table 2
Variability in disc weight and the effect of Hct, Vb on Vest among 3 types of paper.
Paper Disc weight (mg) Effect of Hct and Vb on Vest
Mean CV (%) Mean (SD) ˇHct ˇVb R
2 ErrorHct ErrorVb
N03 9.10 4.1 15.87 (1.22) 0.68* 0.41* 0.62 12.8% 9.8%




































w31ET CHR 9.59 2.3 19.95 (1.95)
ct was centralized at 50% and Vb was centralized at 35 (mL); ˇHct, ˇVb : standardiz
* p<0.001.
orrected for Hct, the accuracy of the DBSmethod can be improved.
or the other two types of paper the lower R2 value suggested that
he variation in Vest is less explained by the Hct and Vb. In addition,
he contributions of these parameters are not unique because ˇHct
nd ˇVb vary among different paper types (Table 2).
The difference in Hct ranged from 20 to 50%. This produced an
rrorHct of 12.8% with Whatman N03, 22.5% with Whatman 31ET
HR and up to 26.8% with Whatman 903. With Whatman 31ET
HR the ErrorVb was only 0.9% and this suggests the bias was not
xplained by Vb. However, with Whatman N03, the bias caused by
b can reach 9.8%. The Whatman 31ET CHR showed a high correla-
ion between the bias of Vest and Hct. Based upon these results
he Whatman 31ET CHR was selected for the method develop-
ent.
The extract in water was dark and not suitable for injecting into
he LC–MS/MS system. We did not intend to develop another step
o clean this extract because it required amore complicated proce-
ure. In addition, MFX appeared to be poorly extracted by ACN or
hemixture of ACN:MeOH (16:84, v/v) because a very low response
as observed. The extract in MeOH was clear and produced a high
hromatographic response. By adding 10 or 20% percent of water,
he chromatographic response was improved. However, with 20%
ater, the extract became darker and therefore the mixture of
0% water in MeOH was selected. During the optimization of the
xtraction peak height responses increasedwith increasing sonica-
ion time. The maximum extraction performance was achieved at
0min, where no signiﬁcant difference was observed between 60
nd 100min (p=0.43) (Fig. 1). Therefore, 60min of sonication was
elected to be used in the method validation.
.2. Method validation.2.1. Selectivity and interference
No interfering peaks at the retention time of MFX and
yanoimipramine were observed in the chromatograms of 5
lank blood DBS samples. The responses of blank DBS sam-
les were lower than 4% of those of the LLOQ DBS. These
ig. 1. Inﬂuence of sonication time on the response of DBS extract (n=5). Result
as presented as mean± SD.4* 0.03 0.89 22.5% 0.9%
ression coefﬁcient of Hct and Vb; R2: total correlation coefﬁcients of the model.
results showed that the method is selective and speciﬁc
(Fig. 2).
3.2.2. Linearity, accuracy and precision
Calibration regression lines (n=3) were linear in the
range of 0.05–6mg/L with correlation coefﬁcients (R2)
of 0.9986±0.0015. The attained regression equation is:
y=0.1376(SD=0.0156) x+0.00026 (SD=0.0014).
The results of inter and intra-day reproducibility, with respect
to bias and precision were within accepted range for all QC levels,
with a maximum bias of −8.1% and a maximum CV of 8.7%. The
maximum bias and CV of the OC samples after correcting for the
dilution were −11.1% and 5.8%, respectively (Table 3).
During method development, carry-over was observed and re-
injections of blank samples for at least 4 times were needed to
totally eliminate the carry-over effect. Consequently, 5 injections
of blank sample were used after a HIGH level sample to resolve
carry-over during validation.
3.2.3. Recovery
High recoveries of 84.5%, 85.1% and 92.6% for QC LOW, MED
and HIGH were achieved and no signiﬁcant matrix effect was
observed (Table 4). Furthermore, no signiﬁcant ion suppression or
ion enhancement visually presented at the retention time of MFX
(1.5min.) or cyanoimipramine (2.0min.) during ion suppression
testing with post-column infusion (Fig. 3).
3.2.4. Stability
The stability of processed samples in the auto-samplerwas eval-
uated at 24 and 48h and complied with the validation criteria. For
long-termstability, theDBSsampleswere stable at roomconditions
for 2 and 4weeks. However, high humidity or high temperature
signiﬁcantly accelerated the degradation of MFX in DBS as the
MFX amounts decreased up to −33.5% bias (Table 5). This indicates
that the samples should not be exposed to high temperatures and
extremely high humidity.
3.3. Inﬂuence of Hct and Vb
The regression equation between Vest and Hct was
Vest = 19.98+0.1398× (Hct-35) (R2 =0.81).
From this result,Vstd of 19.98 and b of 0.1398were applied to Eq.
(2). Extreme Hct percentages showed high analytical biases before
correcting. The difference of uncorrected concentrations between
lowest and highest Hctwas approximately 40%. After correcting for
Hct, the biases were lowered and fell within the accepted range of
15% (Fig. 4).
The Vb showed to have an effect on the concentration by less
than 15% bias. The Vb showed to be directly proportional to the
concentration of the DBS. Even though the volume of the DBS has
a minor effect on the concentration of the punched area of the
DBS, it does affect the accuracy of the analysis within validation
requirements (Fig. 5).













Lig. 2. Represent chromatogram. Chromatogram of cyanoimipramin (a) and moxiﬂ
LOQ DBS (MFX=0.05mg/L) (C) and a patient ﬁnger prick DBS (MFX=1.49mg/L) (D
.4. Clinical validation
For clinical validation, the plasma, venous DBS and DBS from
nger prick samples were taken from 6 tuberculosis patients with
ematocrit values of 26, 37, 33, 41, 35 and 38%. The simple lin-
ar regression showed excellent correlations between the plasma
evel and the DBS level: ﬁnger prick DBS, R2 =0.996 (n=18); venous
BS, R2 =0.973 (n=36). Using a Passing Bablok regression, the
btained slopes of regression lines between DBS and plasma con-
entrations was signiﬁcantly higher than 1 (95% CI: ﬁnger prick
able 3









Day 1 LLOQ (0.05) 0.053 6.8 5.8
LOW (0.15) 0.146 8.7 −2.6
MED (2.50) 2.572 2.4 2.9
HIGH (5.00) 5.244 1.7 4.9
OC (10.00) 10.343 5.5 3.4
Day 2 LLOQ (0.05) 0.051 4.9 2.8
LOW (0.15) 0.138 3.5 −8.1
MED (2.50) 2.360 3.3 −5.6
HIGH (5.00) 4.705 2.4 −5.9
OC (10.00) 8.892 2.3 −11.1
Day 3 LLOQ (0.05) 0.050 5.4 0.3
LOW (0.15) 0.153 2.8 2.2
MED (2.50) 2.388 5.5 −4.5
HIGH (5.00) 4.968 3.2 −0.6
OC (10.00) 8.955 5.8 −10.4
Inter-day LLOQ (0.05) 0.051 5.8 3.0
LOW (0.15) 0.146 6.9 −2.8
MED (2.50) 2.440 5.4 −2.4
HIGH (5.00) 4.972 5.1 −0.6
OC (10.00) 9.397 8.7 −6.0
LOQ: lower limit of quantiﬁcation; MED: medium; OC: over the calibration curve.n (b) in a blank DBS extracted by blank extracting solvent (A); in a blank DBS (B), a
acted by extracting solvent with internal standard (cyanoimipraimin=0.3mg/L).
DBS, 1.32–1.77; venous DBS, 1.50–1.66), and thus shows systemic
differences between DBS and plasma concentrations (Fig. 6). A
comparable result between ﬁnger prick DBS and venous DBS con-
centrations was observed: y=1.01x−0.05 (95% CI slope: 0.92–1.11
and intercept: −0.23 to 0.01).4. Discussion
We developed a method of analysis for routine monitor-
ing of MFX using dried blood spot sampling. Our method
Fig. 3. Representative ion suppression chromatograms obtained from post-column
infusion experiments with blank DBS samples. (a) cyanoimipramin; (b) moxi-
ﬂoxacin.
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Table 4
Matrix effect and recovery of the DBS method (n=5).
QC level (nominal conc.) (mg/L) Solution Response Matrix effect (%) (C/B-1) Recovery (%) (A/C)
Mean CV (%)
LOW (0.15) A 0.020 6.0 −3.4 84.5
B 0.024 3.7
C 0.024 3.8
MED (2.50) A 0.335 2.5 −11.9 85.1
B 0.446 5.1
C 0.393 1.8
HIGH (5.00) A 0.676 3.3 −5.1 92.6
B 0.769 2.0
C 0.730 1.2
A, B and C: response (peak high ratio) of solution A, B and C.
Table 5
Stability after 2 and 4weeks stored in different conditions (n=5).
Condition QC level (nominal conc.) (mg/L) 2-Week stability 4-Week stability
Mean conc. (mg/L) CV (%) Bias (%) Mean conc. (mg/L) CV (%) Bias (%)
−80 ◦C LOW (0.15) 0.156 3.5 4.1 0.161 4.3 7.4
HIGH (5.00) 4,886 1.8 −2.3 5.324 4.9 6.5
Normal LOW (0.15) 0.158 4.2 5.5 0.158 6.0 5.4

















r50 C LOW (0.15) 0.124
HIGH (5.00) 3,869
Humidity LOW (0.15) 0.117
HIGH (5.00) 3,325
as based on punching and extracting a part of the collected
lood spot using LC/MS/MS. Validation was performed accord-
ng to the guidelines for bioanalytical method validation. Effect
f Hct and Vb were evaluated as part of this validation. The
ethod is suitable for clinical pharmacokinetic studies and rou-
ine monitoring of MFX in daily practice. To the best of our
nowledge this is the ﬁrst described validation using DBS for
FX.
The Hct value and blood volume showed to have a relation with
he size of blood spot. Blood with a high Hct shows an increased
iscosity resulting in a smaller bloodspot. This factor needs to be
ddressed if the blood is not obtained with a volumetric capil-
ary and only part of the spot is extracted and analyzed. However,
ampling with a ﬁnger prick without volumetric capillary is eas-
er and cheaper and can therefore be preferred in case of sampling
ig. 4. Inﬂuence of Hct on analytical result and the correction (n=5). Before correction for
ectangles dot line; HIGH: closed circles, solid line.5.8 −17.1 0.112 4.5 −25.4
1.4 −22.6 3.503 6.2 −29.9
31.9 −21.7 0.124 17.1 −17.4
39.2 −33.5 4.518 14.4 −9.6
in remote rural areas. The impact of Hct and Vb on the accuracy
of DBS analysis should be emphasised during method validation.
Our results showed that with a Hct range from 20 to 50%, a signiﬁ-
cant difference of 22.5% in Vest was observed and therefore results
should be corrected for Hct value. The correction can help to reduce
the bias but seems not to totally eliminate it. The remaining small
bias may be the result of other factors such as chromatographic
effect in which the higher Hct, the higher concentration of MFX in
the central part of DBS [13,14]. Wilhelm et al. concluded that Hct
ranged from 20 to 70% produced no signiﬁcant bias of cyclosporin
A concentration in DBS [15]. Nevertheless, even though all biases
were less than 15%, Hct of 20 and 70% seemed to produce a higher
bias. In the clinical application of DBS, LaMarca et al. suggested that
ignoring the impact of Hct could lead to a serious error especially
if Hct levels not within the normal range [20].
Hct: (a); after correction for Hct: (b); LOW: opened square, dash line; MED: closed
D.H. Vu et al. / J. Chromatogr. B
Fig. 5. Inﬂuence of blood volume on analytical result (n=5). LOW: opened square,
dash line; MED: closed rectangles dot line; HIGH: closed circles, solid line.
Fig. 6. Correlation between MFX concentration in venous/ﬁnger prick DBS and
plasma. Correlation between venous DBS and plasma concentration (cross): Pass-















ontercept: −0.15 to 0.03); simple linear regression coefﬁcient R =0.973. Correla-
ion between ﬁnger prick DBS and plasma concentrations (closed circles): Passing
ablok regression line (dash line, n=18), y=1.49x−0.05 (95% CI slope: 1.32–1.77,
ntercept: −0.30 to 0.06); Simple linear regression coefﬁcient R2 = 0.966.
In case of sampling in remote rural areas, patients’ Hct values
re not always available and in that case analytical bias caused by
ct seems unavoidable. However, as TB patients have a mean Hct
alueof35%andourmethod is calibratedon thispoint, the resulting
ifference on the concentration of MFX is generally small.
In a clinical setting, it is difﬁcult to control the size of the DBS
ithout using a volumetric device. The effect of the size of the DBS
n the bias of the result appeared to have less impact than the effect
f the Hct. The concentration of the DBS showed to be directly pro-
ortional to the blood volume it was created with. Although the
olume of the bloodspot showed to be of inﬂuence, the differences
ere well within 15% bias (Fig. 5). Because the discs were punched
ut from the central part of the DBS, the possible reason could be879 (2011) 1063–1070 1069
the chromatographic effect of the paper in which MFX distributed
more in the central and less at the peripheral part. This experiment
proved that it is best to create bloodspots that show low variation
in volume. On the other hand variation in volumes of 30–100L
between patient blood spots will still be within validation require-
ments.
An ion enhancement caused by ethylene diamine tetraacetic
acid (EDTA) on MFX analysis was reported earlier [12]. We also
experienced ionenhancementwithDBSprepared from fresh frozen
plasma that contained citrate as anticoagulant. For that reason, we
selected serum to prepare DBS in which a matrix effect of less than
15% was observed.
In the clinical validation, it appeared that the MFX concentra-
tion in DBS was signiﬁcantly higher than in plasma. This can be
explained by the unequal distribution of MFX between plasma and
blood cells caused by a difference in binding capacity to plasma
proteins and blood cells [24]. The slopes of the regression lines
of 1.49 (95% CI: 1.32–1.77) for ﬁnger blood/plasma ratio and 1.59
(95% CI: 1.50–1.66) for venous blood/plasma ratio showed a higher
concentrations in blood than in plasma. Despite these differences,
excellent regression correlations were observed. The ratio can be
used to translate the DBS concentration into a plasma concentra-
tion. Comparable MFX concentrations between DBS from ﬁnger
prick and venipuncture were observed and thus suggested a simi-
lar MFX concentration between the venous and the ﬁnger capillary
blood. This result also conﬁrmed that the DBS sampling from the
ﬁnger prick blood without a volumetric device was as reliable
as using pipette. Although the free drug concentration of MFX
cannot be calculated based on a DBS result, it still enables the
attending physician tomake clinical decisions on dosingMFX in TB
patients.
5. Conclusion
A rapid and fully validated LC–MS/MS method was developed
for determining MFX in DBS. Vb is of minor inﬂuence compared
to Hct value on the analytical result. MFX concentrations obtained
with DBS are signiﬁcantly higher than the plasma concentrations
because of the blood/plasma ratio but show a good correlation. As
MFX is stable in DBS at room conditions for at least 4weeks, the
methodcan facilitatepharmacokinetic studies andTDMof thisdrug
in remote rural areas.
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